Correction of Liver Steatosis by a Hydrophobic Iminosugar Modulating Glycosphingolipids Metabolism by Lombardo, E. et al.
Correction of Liver Steatosis by a Hydrophobic
Iminosugar Modulating Glycosphingolipids Metabolism
Elisa Lombardo1, Cindy P. A. A. van Roomen1, Gijs H. van Puijvelde2, Roelof Ottenhoff1, Marco van Eijk1,
Jan Aten3, Johan Kuiper2, Herman S. Overkleeft4, Albert K. Groen5, Arthur J. Verhoeven1,
Johannes M. F. G. Aerts1*, Florence Bietrix1
1Departments of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 2Division of Biopharmaceutics, Leiden/
Amsterdam Center for Drug Research (LACDR), Leiden University, Leiden, The Netherlands, 3Department of Pathology, Academic Medical Center, University of
Amsterdam, Amsterdam, The Netherlands, 4Division of Biopharmaceutics, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands, 5Department of
Pediatrics, University Medical Center Groningen, Groningen, The Netherlands
Abstract
The iminosugar N-(59-adamantane-19-yl-methoxy)-pentyl-1-deoxynoijirimycin (AMP-DNM), an inhibitor of glycosphingolipid
(GSL) biosynthesis is known to ameliorate diabetes, insulin sensitivity and to prevent liver steatosis in ob/ob mice. Thus far
the effect of GSL synthesis inhibition on pre-existing NASH has not yet been assessed. To investigate it, LDLR(2/2) mice
were kept on a western-type diet for 12 weeks to induce NASH. Next, the diet was continued for 6 weeks in presence or not
of AMP-DNM in the diet. AMP-DNM treated mice showed less liver steatosis, inflammation and fibrosis. Induction of fatty
acid beta-oxydation was observed, as well as a reduction of plasma lipids. Our study demonstrates that AMP-DNM
treatment is able to significantly correct pre-existing NASH, suggesting that inhibiting GSL synthesis may represent a novel
strategy for the treatment of this pathology.
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Introduction
The metabolic syndrome represents a combination of health
risk factors including abdominal obesity, insulin resistance,
dyslipidemia and hypertension. Non Alcoholic Fatty Liver Disease
(NAFLD) is the hepatic manifestation of the metabolic syndrome.
NALFD includes a large variety of liver derangements ranging
from simple fat accumulation in the parenchymal cells (steatosis) to
non-alcoholic steatohepatitis (NASH) including inflammation and
varying degrees of fibrosis. NAFLD is estimated to affect at least
20% of the general adult population and over 50% of the obese
population [1,2]. In about 30% of NAFLD patients, the disease
can progress into steatohepatitis and cirrhosis [3]. It is expected
that as the prevalence of obesity and metabolic syndrome rises,
NAFLD-associated diseases will be an increasing healthcare
concern and therapeutic measures are thus needed to address this
major health problem [4,5]. Fat accumulation in hepatocytes is the
result of an imbalance between triglyceride synthesis and
degradation. An increased flux and/or endogenous synthesis of
free fatty acids (FFA) may lead to accumulation of triglycerides
within the liver when mitochondrial b-oxidation and VLDL
production and secretion are not sufficient to handle the FFA load.
The molecular mechanisms behind this fat accumulation in
hepatocytes leading to NASH still remain unclear. Hepatic
inflammatory cell recruitment and inflammatory cytokines appear
to play a key role in this process and dietary cholesterol has been
proposed to be an important contributor for the development of
the pathology in hyperlipidemic mouse models [6,7].
We and others have previously shown that two distinct classes of
inhibitors of glucosylceramide (GlcCer) synthase, the rate limiting
enzyme involved in glycosphingolipid (GSL) biosynthesis, im-
proved glycemic control, decreased insulin resistance and reduced
fatty liver development in animal models of obesity i.e. diet-
induced obesity (DIO) mice and ob/ob mice [8–13]. A particular
role for the ganglioside GM3 in insulin sensitivity has become
apparent in recent times. Firstly, Yamashita et al. reported that
mice deficient in GM3 synthase, and thus deficient in the
ganglioside GM3 and higher gangliosides like GM2-glycol, are
protected against insulin resistance and obesity [14]. Inokuchi and
co-workers showed that the ganglioside GM3 interacts directly
with a lysine residue in the insulin receptor [15]. The role of
gangliosides in insulin sensitivity has recently been reviewed
[16,17]. The use of the iminosugar N-(59-adamantane-19-yl-
methoxy)-pentyl-1-deoxynoijirimycin (AMP-DNM) and cer-
amide-mimic Genz-123346 [(1R,2R)-nonanoic acid[2-(29,39-dihy-
dro-benzo [1,4] dioxin-69-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-
ethyl]-amide-L-tartaric acid salt], both inhibitors of GlcCer
synthase, clearly improved liver steatosis [13]. However, the
ability of AMP-DNM to correct liver steatosis and even NASH
when it already has developed, has not yet been investigated.
In the present study, LDLR(2/2) and APOE*3 Leiden mice,
two models sensitive to liver steatosis were allowed to develop
NASH for 12 weeks on high fat-high cholesterol diet and were
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subsequently treated with AMP-DNM for 6 weeks. We observed
that despite the maintenance of the animals on a high fat-high
cholesterol diet, AMP-DNM treatment reduced plasma lipids and
that the steatosis, the inflammatory and fibrotic status were
profoundly improved.
Results
AMP-DNM treatment ameliorates hyperlipidemia and
reverses hepatic steatosis in LDLR(2/2) mice
In the present study, 40 LDLR(2/2) mice were fed a western-
type diet to induce NASH and were subsequently treated with two
different doses of AMP-DNM to achieve the dosing level of 50 and
100 mg AMP-DNM. kg bw21.day21. AMP-DNM supplementa-
tion did not affect the behaviour of the animals. At the dose of
100 mg AMP-DNM, the bodyweight of the animals was reduced
compared to the control group and food consumption slightly
decreased after the switch of diet (table S1). This was not observed
in the group treated with 50 mg AMP-DNM. AMP-DNM
treatment induced a dose-dependent decrease of plasma GlcCer
and ceramide (table 1). Whereas the amount of GlcCer was dose-
dependently decreased in the livers of treated animals, ceramide
amounts were not changed (table 1). AMP-DNM also dose-
dependently decreased plasma triglycerides, FFA, and cholesterol
(fig. 1A–C). We also determined the effect of AMP-DNM
treatment on hepatic concentration of higher glycosphingolipids:
lactosylceramide (Laccer); globotriaosylceramide (Gb3) and gan-
gliosides (table 2). The neutral glycosphingolipids LacCer and Gb3
were reduced by AMP-DNM treatment. The most abundant
ganglioside was GM2-glycol. It was significantly reduced by drug
treatment. This was not seen for the less abundant GM3.
We then determined the effect of AMP-DNM on liver steatosis.
First liver weight was significantly reduced in a dose-dependent
fashion (25% reduction with 50 mg AMP-DNM and 32%
reduction with 100 mg AMP-DNM, p,0.01). Analyses of
morphology and fat content on liver sections stained with H&E
(fig. 2A) and Oil-red-O (fig. 2B) showed that after 12 weeks on
western-type diet feeding, livers of LDLR(2/2) contained micro
and macro-lipid droplets, which were slightly increased in number
and in size after 18 weeks of diet. By contrast, the animals treated
with 50 mg AMP-DNM showed a dramatic reduction in the
amount of hepatic lipid droplets, whereas at the dose of 100 mg
AMP-DNM, virtually no lipid droplets were present. Biochemical
analysis of lipids confirmed a dose-dependent reduction of hepatic
triglycerides (fig. 2C). Free cholesterol content was significantly
reduced at the dose of 100 mg AMP-DNM (fig. 2D).
AMP-DNM treatment modulates hepatic lipogenesis and
glucose production in LDLR(2/2) mice
AMP-DNM ameliorates glucose homeostasis and insulin
sensitivity in obese rodents [9,11,12,18]. In LDLR(2/2) animals,
we observed that blood glucose levels were significantly lower at
the end of the treatment compared to control animals (fig. 3A).
Insulin levels also tend to decrease with the treatment (fig. 3B).
The homeostasis model assessment (HOMA) index was signifi-
cantly reduced in treated animals (fig. 3C). As a consequence of
the improved glucose homeostasis, the percentage of glycated
haemoglobin was notably reduced as well (fig. 3D).
Sterol regulatory element binding protein 1c (SREBP1c) is a
transcription factor activated by insulin and responsible for the
transcription of numerous genes involved in fatty acid synthesis.
Despite insulin resistance for the glucose homeostasis pathway, it
has been reported that hyperinsulinemia triggers the activation of
SREBP-1c and consequently fatty acid synthesis [19]. As
anticipated, we observed that the western-type diet induced an
up-regulation of SREBP1 (fig. 4) and some of its target genes, i.e.
fatty acid synthase (FAS) and stearoyl-CoA desaturase (SCD1).
AMP-DNM treatment normalized expression of these genes.
Figure 1. Effect of AMP-DNM treatment on plasma lipids in
LDLR(2/2) mice. Mice were fed a western-type diet for 18 weeks, and
received in the last 6 weeks either 0, 50 or 100 mg AMP-DNM. Plasma
concentration of triglycerides (A), free fatty acids (FFA) (B) and
cholesterol (C) after 18 weeks of chow diet (chow), 12 weeks of
western-type diet (12w) or 18 weeks of western-type diet with or
without AMP-DNM treatment at the indicated doses. *p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0038520.g001
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Moreover, we observed that the western-type diet induced
expression of PDK4 and glucose-6-phosphatase. Animals treated
with AMP-DNM showed corrected expression of both genes. Of
interest, CPT1a and PCG1a were increased by AMP-DNM
treatment and levels of LCA mRNA tended to be also higher with
drug treatment at the highest dose (fig. 4). These findings suggest
that fatty acid beta-oxidation is increased by AMP-DNM
treatment. Taken together, our data strongly suggest that the
treatment with AMP-DNM increases insulin sensitivity in the
livers of treated animals, reduces lipogenesis and promotes fatty
acid beta-oxidation.
AMP-DNM treatment reduces hepatic inflammation and
fibrosis
Next, we examined the effect of AMP-DNM treatment on
hepatic inflammation (fig. 5). Detailed immunohistochemical
analysis on liver sections stained with the macrophage marker
CD68 (Fig. 5A) revealed that after 12 and 18 weeks of western-
type diet, the Kuppfer cells (the resident macrophages of liver)
became foamy. At the dose of 50 mg AMP-DNM, Kuppfer cells
showed an intermediate phenotype with a reduction of their size.
At the dose of 100 mg AMP-DNM, Kuppfer cells looked even
closer to normal, almost equal in size to those in animals on chow
diet.
Gene expression profiles of inflammatory markers were also
monitored (fig. 5B). After 18 weeks of western-type diet the
expression of the macrophage marker F4/80 was increased 4-fold,
the chemokine (C-C motif) ligand 2 (CCL2)/monocyte chemoat-
tractant protein 1 (MCP-1) 15-fold, and CD11c 3-fold.
We also analysed expression levels of Glycoprotein Nonmeta-
static Melanoma Protein B (GPNMB) also called osteoactivin, a
new marker of monocyte to macrophage differentiation [20]. On
normal chow diet, GPNMB was poorly expressed but feeding with
the western-type diet resulted in a strong up-regulation of its
expression (i.e. 300-fold increase after 18 weeks of western-type
diet). AMP-DNM treatment resulted in a dose-dependent
reduction of expression of each of these markers. At the dose of
100 mg AMP-DNM, the reduction was even larger. It suggests
that the highest dose of AMP-DNM completely corrected the
effect of the western-type diet on liver inflammation.
An important feature in NASH is the progression towards liver
fibrosis. To monitor this aspect, we stained sections with Sirius-
red. In all groups of animals, positive collagen staining was
observed and was localized near vessels of periportal and
centrolobular regions. After 12 and 18 weeks of western-type diet,
collagen staining in these two areas was higher than in animals on
chow diet. Collagen content was slightly reduced as a consequence
of AMP-DNM treatment (fig. 6A). Immunohistochemistry staining
of activated stellate cells with anti-SMA antibody and gene
expression analysis of SMA confirmed this finding (fig. 6B, C).
Gene expression profiles of the collagen 1 alpha (col 1a) and
transforming growth factor beta (TGFb) were also monitored
(fig. 6C). Both these markers were considerably increased with the
western-type diet, whereas the AMP-DNM treatment normalized
their expressions levels.
AMP-DNM also corrects hepatic steatosis in APOE*3
Leiden
We examined also the impact of AMP-DNM treatment on fatty
liver of APOE*3 Leiden mice that were exposed for 12 weeks to a
1% cholesterol, 15% fat diet. The switch of diet induced a slight
reduction of the animal bodyweights treated with either 50 or
100 mg AMP-DNM. No major changes were observed concern-
ing the food consumption (table S2). The liver of these animals
after 12 weeks of diet showed steatosis, but no clear fibrosis as
compared to the LDLR(2/2) mice (fig. 7A). Animals were
subsequently switched for 6 weeks to 0.25% cholesterol, 15% fat
diet with or without AMP-DNM. The drug treatment lowered as
expected the levels of glucosylceramide in plasma and liver of
treated animals (tables S3 and S4) and it dramatically corrected
liver steatosis that was still prominent in the control animals
(fig. 7A). AMP-DNM also resulted in corrections in liver
triglyceride and cholesterol content (fig. 7B).
Discussion
We have previously demonstrated in leptin-deficient ob/ob
mice that AMP-DNM treatment reduced liver steatosis associated
with a restoration of liver insulin signaling [9]. Also hepatic fatty
acid synthesis and glycogen storage were normalized. Two other
inhibitors of GlcCer synthase, Genz-123346 and Genz-112638,
also corrected liver steatosis in diet-induced obese (DIO) mice
[10,13].
A limitation of the leptin-deficient ob/ob and DIO models is
that the mice do not develop steatohepatitis or liver fibrosis as is
observed in humans [21]. LDLR(2/2) mice fed a western-type
diet consisting of a moderate amount of fat (15%) and cholesterol
(0.25%) offer a better model to investigate NASH. The animals,
Table 1. Plasma and liver glucosylceramide (glccer) and
ceramide (cer) concentrations in LDLR(2/2) mice fed a
western-type diet for 18 weeks, receiving in the last 6 weeks
either 0, 50 or 100 mg AMP-DNM.
plasma (nmol.ml21) liver (nmol.g21 liver)
glccer cer glccer cer
chow 11.560.3** 6.760.4** 38.567.0 123.1611.2
12w 81.464.6 45.265.2 46.163.8 131.965.8
18w 85.566.7 45.162.6 62.565.5 150.867.7
50 mg 32.063.2** 35.364.7 33.463.9*** 150.1611
100 mg 10.160.8** 17.760.7** 21.761.3*** 161.768
Data are expressed as mean 6 SEM of 5 (plasma) and 10 (liver) mice.
***, p,0.001.
doi:10.1371/journal.pone.0038520.t001
Table 2. Liver lactosylceramide (Laccer) and
globotrihexosylceramide (Gb3) and gangliosides (GM2-gl and
GM3) concentrations in LDLR(2/2) mice fed a western-type
diet for 18 weeks, receiving in the last 6 weeks either 0, 50 or
100 mg AMP-DNM.
liver (nmol.g21 liver)
Laccer Gb3 GM2-gl GM3
12w 16.461.3 7.260.6 255.9619.6 19.868.5
18w 22.861.2 6.360.8 308.7622.5 23.263.4
50 mg 16.561.1** 2.860.3** 338.8614.5 24.664.1
100 mg 14.661.5*** 0.9.60.1*** 173.4613.8*** 16.762.6
Data are expressed as mean 6 SEM of 5 mice.
**, p,0.01;
***, p,0.001.
doi:10.1371/journal.pone.0038520.t002
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Figure 2. Effect of AMP-DNM treatment on liver steatosis in LDLR(2/2) mice. Mice were fed a western-type diet for 18 weeks, and received
in the last 6 weeks either 0, 50 or 100 mg AMP-DNM. (A) Representative photomicrographs of hematoxylin-eosin staining and Oil red O staining (B) of
livers section after 18 weeks of chow diet (chow), 12 weeks of western-type diet (12w) or 18 weeks of western-type diet with or without AMP-DNM
treatment at the indicated doses (original magnification610). (C) Triglyceride content and (D) cholesterol content in liver of animals for the indicated
groups. *p,0.05; **p,0.01. #p,0.01 for esterified cholesterol.
doi:10.1371/journal.pone.0038520.g002
Figure 3. Effect of AMP-DNM treatment on insulin sensitivity in LDLR(2/2) mice. Mice were fed a western-type diet for 18 weeks, and
received in the last 6 weeks either 0, 50 or 100 mg AMP-DNM. (A) Glucose concentration and (B) insulin concentration in plasma of fasted animals. (C)
Homeostasis model assessment (HOMA) index and (D) percentage of glycated heamoglobin 1c (HbA1c). *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0038520.g003
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showing a human ‘‘like’’ lipoprotein profile, rapidly develop
hepatic steatosis and inflammation [22]. We have previously
observed in this model that treatment with AMP-DNM from the
start of the diet reduces liver triglyceride content [23]. To study
the ability of AMP-DNM to also correct hepatic manifestations of
the metabolic syndrome, LDLR(2/2) mice were kept on a
western-type diet for 12 weeks to induce NASH. Next, the diet was
continued for 6 weeks in the presence or absence of AMP-DNM in
the diet. Our study demonstrates that AMP-DNM treatment is not
only able to prevent liver steatosis, but is also able to significantly
correct pre-existing NASH. AMP-DNM treated mice showed less
liver steatosis and inflammation with a liver phenotype closely
resembling that of matched LDLR(2/2) mice fed a standard
chow diet. In APOE*3 Leiden mice, another hyperlipidemic
model sensitive to hepatic steatosis, AMP-DNM treatment
corrected liver accumulation of fat and reduced inflammation in
a similar fashion to what was observed with LDLR(2/2) mice. In
this experiment set-up, animals were first fed with a high-fat high
cholesterol diet (1% cholesterol, 15% fat) for 12 weeks and fed for
6 following weeks a western-type diet (0.25% cholesterol, 15% fat)
supplemented with either 0, 50 or 100 mg AMP-DNM. It has to
be noted that the decrease in cholesterol in the diet tends by itself
to decrease liver lipids in the control animals (table S3) whereas we
observed a poor effect of the reduction of lipids in the diet on
Figure 4. Effect of AMP-DNM treatment on genes involved in lipid metabolism in livers of LDLR(2/2) mice. Mice were fed a western-
type diet for 18 weeks, and received in the last 6 weeks either 0, 50 or 100 mg AMP-DNM. Expression levels normalized to Acidic ribosomal
phosphoprotein (36B4). *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0038520.g004
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plasma cholesterol and triglycerides. The AMP-DNM treatment
induced a significant and prominent decrease of these parameters
in both compartment.
The underlying mechanism by which AMP-DNM treatment is
able to correct NASH manifestation is intriguing. In the
LDLR(2/2) mice the most prominent ganglioside in liver is
GM2-glycol, rather than GM3. AMP-DNM treatment led to a
major reduction in GM2-glycol, accompany the correction of liver
steatosis. It may be speculated that GM2-glycol, rather than GM3,
causes insulin resistance in the LDLR(2/2) mice liver. Hyper-
insulinemia has been proposed to promote liver steatosis [19] and
hyperinsulinemic patients with NASH treated with insulin-
sensitizing agents show improvements of liver steatosis [24]. It is
well known that inhibitors of GlcCer synthase like AMP-DNM
and Genz-123346 are also able to improve insulin sensitivity in
various rodent models by virtue of lowering glycosphingolipids
[16,17]. LDLR(2/2) mice treated with AMP-DNM in this study
showed an improvement of the HOMA index and a concomitant
decrease of hepatic lipogenesis and increased beta-oxidation.
Recent experiments with ob/ob mice also revealed that AMP-
DNM causes major changes in hepatic lipid metabolism. The rates
of fatty acid beta-oxidation and glucose oxidation were determined
using metabolic cages, revealing that shortly after exposure to
AMP-DNM, fat oxidation was nearly doubled (0.07 to
0.16 kcal.h21 in the nocturnal period and 0.10 to 0.19 kcal.h21
in the diurnal period). On the opposite, carbohydrate oxidation
was markedly reduced by AMP-DNM treatment (0.43 to
0.28 kcal.h21 in the nocturnal period and 0.34 to 0.20 kcal.h21
in the diurnal period [25]. Other researchers have also reported
beneficial effect of iminosugars on hepatic fatty acid oxidation.
Similar to our findings with AMP-DNM, Tsuduki et al reported
that intake of 1-deoxynojirimycin promotes hepatic beta-oxidation
and suppresses lipid accumulation in rat liver [26]. Kobayashi and
co-worker reported similar effects induced by mulberry extracts
known to be rich in simple iminosugars [27]. It is likely that these
metabolic changes, following improved insulin sensitivity, contrib-
Figure 5. Effect of AMP-DNM treatment on hepatic inflammation in LDLR(2/2) mice. Mice were fed a western-type diet for 18 weeks, and
received in the last 6 weeks either 0, 50 or 100 mg AMP-DNM. (A) Representative photomicrographs of immunohistochemical staining of CD68 of the
indicated mice (original magnification610). (B) Gene expression of inflammation markers. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0038520.g005
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ute to the lowering of triglycerides in hepatocytes and the
correction of steatosis observed in LDLR(2/2) and APOE*3
Leiden mice (figure S1 and S2).
Of note, lowering of glycosphingolipids by specific genetic
knock-down of GlcCer synthase in hepatocytes does not reduce
liver triglycerides in mice exposed to a high fat diet [28]. It seems
unlikely that the insulin-sensitizing effect of AMP-DNM alone
explains the observed effects on hepatic inflammation and fibrosis.
Presumably the earlier described anti-inflammatory actions of
AMP-DNM play a key role as well [12,29].
In the past years, several studies showed that ER stress response
plays an important role in lipid metabolism and is linked to fatty
liver disease [30–32]. The role of glycosphingolipids in ER stress
response has not been extensively studied yet. A recent study on
pancreatic MIN6 b-cell has revealed that ER stress is associated
with increased GlcCer and that it is ameliorated by transfection of
cells with glucosylceramide synthase [33]. Ceramide concentration
is not changed. In our previous study on AMP-DNM treatment of
ob/ob mice, microarray data for liver did not reveal any
significant changes in expression of proteins involved in pathways
associated with ER stress [9]. It nevertheless remains of interest to
study in more detail the possible role of (glyco)sphingolipids in ER
stress responses and related effects on lipid homeostasis.
Liver natural killer T (NKT) cells are thought to be able to
ameliorate steatosis and NKT cells numbers are reduced in
steatotic livers of human subjects and ob/ob mice [34,35]. We
anticipated that AMP-DNM treatment might modulate the
hepatic NKT cell population. Non-parenchymal cells were
therefore isolated from livers of treated animals and screened for
NKT markers by flow cytometry (fig. S3A). The percentage of
hepatic NKT cells upon AMP-DNM treatment did not change,
suggesting that this cell population was not causing the observed
correction of NASH. CD4+ - and CD8+ T-cell populations were
also unaffected by AMP-DNM (fig. S3B).
AMP-DNM exerts a positive effect on cholesterol homeostasis
by promoting biliary sterol secretion and fecal excretion [23].
Increased hepatic free cholesterol in obese, diabetic mice is a
known critical factor in the development of nonalcoholic
Figure 6. Effect of AMP-DNM treatment on liver fibrosis in LDLR(2/2) mice.Mice were fed a western-type diet for 18 weeks, and received in
the last 6 weeks either 0, 50 or 100 mg AMP-DNM. (A) Representative photomicrographs of Sirius-red staining of liver sections of the indicated mice
(original magnification610). (B) Representative photomicrographs of immunohistochemical staining of activated stellate cells (original magnification
610). (C) Gene expression of fibrosis marker. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0038520.g006
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steatohepatitis [36,37]. Of interest, AMP-DNM treatment at the
highest dose of 100 mg. kg bw21. day21 led to a significant
decrease in free cholesterol content of liver of the LDLR(2/2)
mice. We also observed a strong dose-dependent reduction of
plasma cholesterol in LDLR(2/2) animals treated with AMP-
DNM. All this was accompanied by reduction of F4/80 positive
cells in the liver (fig. S3C). AMP-DNM treatment clearly
decreased (macrophage) inflammation in the liver. The positive
effects on cholesterol homeostasis exerted by AMP-DNM may
contribute to the reversal in hepatosteatosis. High cholesterol in
the western-type diet is detrimental since it drives inflammation
due to uptake of modified cholesterol-rich lipoproteins by Kuppfer
cells [38]. We therefore would like to propose that AMP-DNM, by
improving cholesterol homeostasis, causes a beneficial reduction of
Kuppfer cell activation.
In conclusion, our study shows clearly that drug treatment is
sufficient to swiftly correct the liver manifestations of NASH in two
different animal models with improved insulin sensitivity, promo-
tion of fatty acid beta-oxidation and reduction of inflammation.
Materials and Methods
Materials
AMP-DNM was synthesized as previously described [39,40]. All
solvents and reagents used were of analytical grade.
Mice and diets
Experiments were performed with the approval of the local
Ethical Committee for Animal Experiments.
40 female LDLR(2/2) mice (8–12 weeks-old) were fed a
western-type diet (0.25% cholesterol, 15% fatty acids; Arie Blok,
Woerden, the Netherlands) for 12 weeks to induce NASH and 10
mice were sacrificed. The 30 remaining mice were subdivided into
3 groups of 10 animals, one group continued the same diet for
another 6 weeks, the second group received the same diet
supplemented with 0.3 g AMP-DNM per kg diet to obtain the
calculated dose of 50 mg AMP-DNM. kg bw21. day21 and the
third group received 0.6 g AMP-DNM per kg diet to obtain
100 mg AMP-DNM. kg bw21. day21. In parallel, one group of 5
LDLR(2/2) mice was kept on chow diet. In a second experiment,
40 female APOE*3 Leiden (8–12 weeks-old) were fed a high fat-
high cholesterol diet (1% cholesterol, 15% fatty acids) for 12 weeks
and 10 mice were sacrificed. The 30 remaining mice continued
with a western-type diet (0.25% cholesterol, 15% fatty acids)
supplemented or not with two different doses of AMP-DNM to
obtain the calculated dose of 50 mg and 100 mg AMP-DNM. kg
bw21. day21.
Plasma and tissue sampling
Blood samples of non-fasted animals were collected via the tail
vein at the time points indicated in the figures. At the end of the
experiments, blood samples were collected by abdominal aorta
Figure 7. Effect of AMP-DNM treatment on liver steatosis in APOE*3 Leiden mice. Mice were fed a high cholesterol-high fat diet (1%
cholesterol, 15% fat) for 12 weeks and were fed for 6 weeks more a western-type diet (0.25% cholesterol, 15% fat) supplemented with either 0, 50 or
100 mg AMP-DNM. Representative photomicrographs of hematoxylin-eosin staining (A) and Oil red O staining (B) of livers section after 12 weeks of
high cholesterol-high fat diet (12w) or after 12 weeks of high fat-high cholesterol diet followed by 6 weeks of western-type diet (18w) with or without
AMP-DNM treatment at the indicated doses (original magnification610). (C) Triglycerides content and (D) cholesterol content in liver of animals for
the indicated groups. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0038520.g007
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puncture and plasma samples were stored at 220uC. Livers were
quickly excised and weighed, and parts were snap-frozen in liquid
nitrogen and stored at 280uC, or fixed in 10% buffered formalin
and embedded in paraffin.
Analytical procedures
Blood glucose levels were determined in plasma of fasted
animals using a hand-held Glucometer (Ascensia Elite; Bayer
A.G., Leverkusen, Germany) one week before the sacrifice of the
animals. Hemoglobin A1c levels were measured using a single
measurement A1C now device (Metrika, Sunnyvale, CA). Insulin
levels were determined by enzyme-linked immunosorbent assay
(Crystal Chem Inc., Downers Grove, IL). Free cholesterol, total
cholesterol, and triglycerides in liver samples were determined
after lipid extraction according to Folch [41] using a colorimetric
enzymatic kit (Biolabo, Maizy, France). Cholesterol and triglyc-
eride levels in plasma were determined using the same assay. FFA
level in plasma were determined using a colorimetric enzymatic kit
(Wako Chemicals Gmbh, Neuss, Germany). Ceramide and
GlcCer were determined after Folch extraction as previously
describe [11]. Plasma cholesterol concentrations in the main
lipoprotein classes were determined in pooled plasma samples of
each group (5 mice) separated by high performance gel filtration
chromatography [42].
Histology
Paraffin embedded liver sections (7 mM) were de-waxed and
stained with hematoxylin-eosin for general histology, or with 0.2%
picro-sirius red to detect fibrillar collagen deposits. To detect
neutral lipids, cryostat sections of 7 mM were stained with 0.3%
Oil Red O. For detection of macrophages/monocytes, a rat
polyclonal anti-CD68 was used (Serotec, Oxford UK) and an anti-
alpha smooth muscle actin (SMA) antibody to visualize activated
stellate cells (1A4, Abcam, Cambridge, UK). Frozen sections of
livers fixed in cold acetone were incubated one hour at room
temperature with CD68 (1/100 dilution) or SMA antibody (1/100
dilution) followed by incubation for 30 min at room temperature
with the corresponding secondary antibodies. Visualization of the
complex was done with 3,39-diaminobenzidine tetrahydrochloride
(DAB, Immunologic, Duiven, The Netherlands) for 5 min. For all
stainings, haematoxylin (Sigma-Aldrich, Zwijndrecht, the Nether-
lands) was used to counterstain. Primary antibodies were omitted
in negative control samples. Images were captured with a Leica
DFC 420 video camera.
Determination of mRNA levels
Total RNA was isolated from 50–100 mg of liver tissue using
Trizol reagent (Invitrogen, Breda, The Netherlands) and reverse
transcribed with SuperScript II Reverse Transcriptase and
random hexamers (Invitrogen, Breda, The Netherlands) after
treatment with RQ1 Rnase-free Dnase (1 units/2 mg of total RNA,
Promega, Leiden, The Netherlands). Gene expression analysis was
performed on a Bio-Rad MyIQ Single-color Real-Time PCR
Detection System by using the Bio-Rad IQ SYBR Green
Supermix (Bio-Rad Laboratories Inc., Hercules, CA). Expression
levels were normalized to Acidic ribosomal phosphoprotein
(36B4).
Statistical analysis
Values presented in figures concerning the LDLR(2/2) mice
represent mean 6 SEM. Dunnett’s comparison test was
performed between 18 weeks controls and each other group using
GraphPad Prism software. Values presented in figures concerning
the APOE*3 Leiden mice represent mean 6 SEM. Dunnett’s
comparison test was performed between baseline at 12 weeks and
each other group using GraphPad Prism software *, p,0.05;
**, p,0.01; ***, P,0.001.
Supporting Information
Figure S1 Genes expression in livers of APOE*3 Leiden
mice fed a high cholesterol-high fat diet (1% cholesterol,
15% fat) for 12 weeks and fed for 6 more weeks a
western-type diet (0.25% cholesterol, 15% fat) supple-
mented with either 0, 50 or 100 mg AMP-DNM. Expres-
sion levels normalized to Acidic ribosomal phosphoprotein (36B4).
Data are expressed as mean 6 SEM, n = 5. Statistical significance
determined between baseline 12w and other groups with
Dunnett’s comparison test. *p,0.05, **p,0.01, p,0.001.
(DOC)
Figure S2 Effect of AMP-DNM treatment on insulin
sensitivity in APOE*3 Leiden mice fed a high cholester-
ol-high fat diet (1% cholesterol, 15% fat) for 12 weeks
and fed for 6 more weeks a western-type diet (0.25%
cholesterol, 15% fat) supplemented with either 0, 50 or
100 mg AMP-DNM. Data are expressed as mean 6 SEM,
n = 5. Statistical significance determined between baseline 12w
and other groups with Dunnett’s comparison test. *p,0.05,
**p,0.01, p,0.001.
(DOC)
Figure S3 FACs analysis of leucocytes isolated from
livers of LDLR(2/2) mice fed a western-type diet for 18
weeks, receiving in the last 6 weeks either 0, 50 or
100 mg AMP-DNM. (A) CD3 positive cells and natural killer T
(NKT) cells (NK1.1 and CD3 double positive cells). (B) CD4 and
CD8 positive cells. (C) F4/80 positive cells. Data are expressed as
mean 6 SEM, n = 4. Statistical significance between control and
treated groups was determined by Dunnett’s comparison test
**p,0.01; *p,0.05.
(DOC)
Table S1 Effect of AMP-DNM treatment on bodyweight
and food intake in LDLR(2/2) mice fed a western-type
diet for 18 weeks, receiving in the last 6 weeks either 0,
50 or 100 mg AMP-DNM. Data are expressed as mean 6
SEM, n = 10 for bodyweight. Food intake based on the amount of
food left in each cage of treatment (2 to 3 cages per treatment) at
the end of each dosing week.
(DOC)
Table S2 Effect of AMP-DNM treatment on bodyweight
and food intake in APOE*3 Leiden mice fed a high
cholesterol-high fat diet (1% cholesterol, 15% fat) for 12
weeks and fed for 6 following weeks a western-type diet
(0.25% cholesterol, 15% fat) supplemented with either
0, 50 or 100 mg AMP-DNM. Data are expressed as mean 6
SEM, n = 5 for bodyweight. Food intake based on the amount of
food left in each cage of treatment (2 to 3 cages per treatment) at
the end of each dosing week.
(DOC)
Table S3 Plasma lipids concentrations in APOE*3
Leiden mice fed a high cholesterol-high fat diet (1%
cholesterol, 15% fat) for 12 weeks and fed for 6 more
weeks a western-type diet (0.25% cholesterol, 15% fat)
supplemented with either 0, 50 or 100 mg AMP-DNM.
Data are expressed as mean 6 SEM, n = 5.
(DOC)
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Table S4 Liver glycosphingolipids concentrations in
APOE*3 Leiden mice fed a high cholesterol-high fat diet
(1% cholesterol, 15% fat) for 12 weeks and fed for 6
more weeks a western-type diet (0.25% cholesterol, 15%
fat) supplemented with either 0, 50 or 100 mg AMP-
DNM. Data are expressed as mean 6 SEM, n = 5.
(DOC)
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